Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propranolol versus octreotide for prophylaxis of esophageal variceal bleeding in children with portal hypertension
IRCT20260429069207N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- May 2026
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Portal Hypertension (PH) and esophageal varices comparing Octreotide with Propranolol (2 arms). Primary endpoint: Occurrence of esophageal variceal bleeding. Started May 2026; status: completed.
02
Drugs
propranololoctreotide
03
Conditions
Portal Hypertension (PH)esophageal varices
Beyond the preview
Go deeper on IRCT20260429069207N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20260429069207N1.